Predicted protein targets (top 7)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | APP | P05067 | 1/20 | 0.55 |
| ▸ | SELP | P16109 | 9/20 | 0.54 |
| ▸ | SELL | P14151 | 3/20 | 0.52 |
| ▸ | SELE | P16581 | 3/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.49 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.49 |
| ▸ | CETP | P11597 | 1/20 | 0.47 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL22658273 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658269 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658274 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL21537086 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777275 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658272 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL24777277 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658271 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL23957944 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 | |
| SCHEMBL22658268 | 1.00 | APP (0.55) | APPSELPSELLSELEMEN1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 91 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20230338251-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-20230338251-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS, INC. | 2023-10-26 | — | — | US | disclosed |
| US-11744860-B2 | Technology for efficient activation of NKT cells | RIKEN (JP) | 2023-09-05 | — | — | US | disclosed |
| US-20220387461-A1 | CANCER VACCINE | VICTORIA LINK LIMITED (NZ) | 2022-12-08 | — | — | US | disclosed |
| US-20210077627-A1 | METHOD OF TREATING CANCER | INTENSITY THERAPEUTICS, INC. | 2021-03-18 | — | — | US | disclosed |
| US-10888618-B2 | Method of treating cancer | INTENSITY THERAPEUTICS, INC. (US) | 2021-01-12 | — | — | US | disclosed |
| US-20190000760-A1 | NANOPARTICLE-AQUEOUS DISPERSION LIQUID OF GLYCOSPHINGOLIPID | REGIMMUNE CORPORATION (JP) | 2019-01-03 | — | — | US | disclosed |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | LUDWIG INSTITUTE FOR CANCER RESEARCH LTD. (US) | 2018-08-07 | — | — | US | disclosed |
| EP-2654779-B1 | LIPOSOMAL FORMULATION OF NONGLYCOSIDIC CERAMIDES AND USES THEREOF | LUDWIG INST FOR CANCER RES LTD (US) | 2018-02-28 | — | — | EP | disclosed |
| US-20170312356-A1 | MODULATION OF NKT CELL ACTIVITY WITH ANTIGEN-LOADED CD1d MOLECULES | VACCINEX, INC. (US) | 2017-11-02 | — | — | US | disclosed |
| US-20090117089-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS | THE ROCKEFELLER UNIVERSITY (US) | 2009-05-07 | — | — | US | disclosed |
| US-20090048185-A1 | Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2009-02-19 | — | — | US | disclosed |
| US-20090048185-A1 | Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient | JAPAN AS REPRESENTED BY PRESIDENT OF NATIONAL CENTER OF NEUROLOGY AND PSYCHIATRY (JP) | 2009-02-19 | — | — | US | disclosed |
| US-7488491-B2 | Use of glycosylceramides as adjuvants for vaccines against infections and cancer | NEW YORK UNIVERSITY (US) | 2009-02-10 | — | — | US | disclosed |
| US-20080254045-A1 | Therapeutic mixture comprising a non-specific cluster of differentiation-1 (CD1d) complex which comprises beta 2-microglobulin and binds ceramide-like glycolipid antigens for use in treatment of autoimmune disorders | 3I, L.P. | 2008-10-16 | — | — | US | disclosed |
| US-20080145931-A1 | Mature Dendritic Cell Compositions and Methods of Culturing Same | ARGOS THERAPEUTICS, INC. | 2008-06-19 | — | — | US | disclosed |
| EP-1905766-A1 | GLYCOLIPID DERIVATIVE AND THERAPEUTIC AGENT COMPRISING THE SAME AS ACTIVE INGREDIENT | Japan as represented by President of National Center of Neurology and Psychiatry (JP) | 2008-04-02 | — | — | EP | disclosed |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | ALBERT EINSTEIN COLLEGE OF MEDICINE | 2007-10-11 | — | — | US | disclosed |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | THE ROCKEFELLER UNIVERSITY (US) | 2007-10-11 | — | — | US | disclosed |
| US-20070082400-A1 | Mature dendritic cell compositions and methods for culturing same | COIMMUNE, INC. | 2007-04-12 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (13 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20190000760-A1 | NANOPARTICLE-AQUEOUS DISPERSION LIQUID OF GLYCOSPHINGOLIPID | GBA1, GBA2, GALC | APP 2451/4885SELP 377/4885SELL 237/4885 |
| US-10888618-B2 | Method of treating cancer | PBK, GZMB, NPC1L1 | APP 2733/4885SELP 2017/4885SELL 914/4885 |
| US-20090117089-A1 | GLYCOLIPIDS AND ANALOGUES THEREOF AS ANTIGENS FOR NK T CELLS | PBK, CD69, KLRK1 | APP 3313/4885SELP 170/4885SELL 110/4885 |
| US-20220387461-A1 | CANCER VACCINE | TLR9, TLR1, TLR7 | APP 3778/4885SELP 1246/4885SELL 440/4885 |
| US-20070238673-A1 | Ceramide derivatives as modulators of immunity and autoimmunity | CERS2, UGCG, SGMS1 | APP 1999/4885SELP 741/4885SELL 427/4885 |
| US-10039715-B2 | Liposomal formulation of nonglycosidic ceramides and uses thereof | CERS2, CERT1, SGMS1 | APP 1491/4885SELP 643/4885SELL 72/4885 |
| US-11744860-B2 | Technology for efficient activation of NKT cells | CD14, PBK, IL4 | APP 2310/4885SELP 95/4885SELL 16/4885 |
| US-20170312356-A1 | MODULATION OF NKT CELL ACTIVITY WITH ANTIGEN-LOADED CD1d MOLECULES | KLRK1, MICA, UGCG | APP 685/4885SELP 165/4885SELL 132/4885 |
| US-20090048185-A1 | Therapeutic Drug for Suppressing Functions of NKT Cells Containing Glycolipid Derivative as Active Ingredient | CD4, NFATC1, NR1H2 | APP 1726/4885SELP 640/4885SELL 333/4885 |
| US-20210077627-A1 | METHOD OF TREATING CANCER | PBK, GZMB, NPC1L1 | APP 2733/4885SELP 2017/4885SELL 914/4885 |
| US-20230338251-A1 | METHOD OF TREATING CANCER | PBK, GZMB, NPC1L1 | APP 2733/4885SELP 2017/4885SELL 914/4885 |
| US-20080254045-A1 | Therapeutic mixture comprising a non-specific cluster of differentiation-1 (CD1d) complex which comprises beta 2-microglobulin and binds ceramide-like glycolipid antigens for use in treatment of autoimmune disorders | CD74, CERS2, UGCG | APP 801/4885SELP 433/4885SELL 295/4885 |
| US-20070238871-A1 | Glycolipids And Analogues Thereof As Antigens For NKT Cells | CD69, KLRK1, PBK | APP 2638/4885SELP 255/4885SELL 184/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.